In this conversation today, we're going to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities Asia PAC represents for ocular development. We'll also look ahead to the most promising trends shaping the future of ophthalmology trials. 

Host: Amber Burg

Participants: Tanya Richardson Fortrea’s Therapeutic Strategy Head for Neuroscience and Ophthalmology

Lisa Liang, Senior Director of Clinical Operations at Belite Bio.